HEMOSTEMIX Aktie

>HEMOSTEMIX Aktienkurs

0.041 EUR (TradegateBSX)

Ask: 0.045 EUR / 25000 Stück

Bid: 0.037 EUR / 31000 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

HEMOSTEMIX Aktie über LYNX handeln

Intraday

1 Jahr

>HEMOSTEMIX Performance

1 Woche: -4,1%

1 Monat: -22,1%

3 Monate: -23,6%

6 Monate: -38,4%

1 Jahr: -35,5%

laufendes Jahr: -21,0%

>HEMOSTEMIX Aktie

Name:

HEMOSTEMIX INC.

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA4236943060 / A2QQGU

Symbol/ Ticker:

2VF0 (Frankfurt)

Kürzel:

FRA:2VF0, ETR:2VF0, 2VF0:GR

Index:

Webseite:

https://hemostemix.com/

Profil:

Hemostemix Inc., a biotechnology company, specializes in developing treatments for blood-related disorders. The company's primary focus lies in harnessing the regenerative power of the body's own cells to treat various medical conditions. At the core..
>Volltext..

Marktkapitalisierung:

8.51 Mio. EUR

Unternehmenswert:

9.82 Mio. EUR

Umsatz:

EBITDA:

-2.67 Mio. EUR

Nettogewinn:

-2.11 Mio. EUR

Gewinn je Aktie:

-0.02 EUR

Schulden:

2.14 Mio. EUR

Liquide Mittel:

0.72 Mio. EUR

Operativer Cashflow:

-3.22 Mio. EUR

Bargeldquote:

1.5

Umsatzwachstum:

Gewinnwachstum:

-57.12%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

HEMOSTEMIX

Letzte Datenerhebung:

05.04.26

>HEMOSTEMIX Kennzahlen

Aktien/ Unternehmen:

Aktien: 195.25 Mio. St.

Frei handelbar: 78.23%

Leerverk. Aktien: -

Rückkaufquote: -46.92%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -0.1

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -453.77%

Eigenkaprendite: -

>HEMOSTEMIX Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>HEMOSTEMIX Chart & Kurs - Tradegate

>HEMOSTEMIX News

09.03.26 - 16:36	Hemostemix Inc.: Hemostemix Leadership Attending Abundance360 Summit (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 ......

03.02.26 - 15:12	Hemostemix Inc.: Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peri......

16.01.26 - 18:42	Hemostemix Inc.: Hemostemix Receives FDA Support for Its Basket Protocol Approach (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peri......

31.12.25 - 20:54	Hemostemix Inc.: Hemostemix Closes $480,000 Private Placement at $0.12 per Share (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who ......

23.12.25 - 15:18	Hemostemix Inc.: Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01 (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who ......

11.12.25 - 15:54	Hemostemix Inc.: Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv) (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell (A......

11.12.25 - 15:06	Hemostemix Inc.: Hemostemix Grants Stock Options (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its s......

10.12.25 - 17:30	Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000 (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell th......

04.12.25 - 15:18	Hemostemix Inc.: Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for is......

03.12.25 - 20:18	Hemostemix Inc.: Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14 (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier......

02.12.25 - 15:18	Hemostemix Inc.: Hemostemix to Attend DFCon San Antonio and Closed its Private Placement (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preserva......

26.11.25 - 22:30	Hemostemix Inc.: Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first ......

20.11.25 - 15:06	Hemostemix Inc.: Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (......

18.11.25 - 23:18	Hemostemix Inc.: Hemostemix Closes CDN$280,594 Private Placement (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell th......

18.11.25 - 17:42	Hemostemix Inc.: Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Confer......

13.11.25 - 17:06	Hemostemix Inc.: Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - November 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced key highlights from its November 12, 2025 Grand Rounds presentation ......

04.11.25 - 21:18	Hemostemix Inc.: Hemostemix Closes Private Placement of $461,230 (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell the......

30.10.25 - 16:42	Hemostemix Inc.: Hemostemix′s Boots on the Ground in Florida October Update (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (A......

28.10.25 - 20:54	Hemostemix Inc.: Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (A......

22.10.25 - 16:18	Hemostemix Inc.: Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42 (Newsfile)
	Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (A......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram